- About Us
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(BFNH.OB), announced today the March sale of the Nano eNabler(TM) molecular
printer to Louisiana Tech University in Ruston, Louisiana. Louisiana Tech
recently received the third highest rating for nanotechnology education by
Small Times, a respected journal on the nanotech subject.
The Louisiana Tech's Department of Biomedical Engineering Professor Dr.
Mark DeCoster will be using the Nano eNabler technology to study the
patterning of cells -- brain and stem -- in culture; also investigators at
the adjoining building where the Institute of Micromanufacturing is housed
will be studying patterning of nanoparticles and nanowires. The Nano
eNabler(TM) system -- BioForce's flagship product -- is a benchtop
molecular printer that places tiny domains of materials onto surfaces with
nanometer spatial precision.
Dr. DeCoster says he became aware of the Nano eNabler molecular printer
from an article and was intrigued with the systems' ability to deposit and
pattern proteins that will retain biological activity. "My initial idea is
to use the Nano eNabler printer to pattern brain cells. We have
successfully begun research in this area using photomasking and
layer-by-layer lift off techniques with proteins and polymers. While the
structural integrity of molecules deposited in this way is maintained,
biological activity -- for example, enzymes -- is most likely diminished or
destroyed." DeCoster is using the Nano eNabler system to remedy this
problem and deposit proteins that retain biological activity to investigate
the influence on brain cell patterning.
BioForce Nanosciences develops and commercializes nanotech tools and
solutions for the life sciences. Founded over a decade ago, BioForce has
been providing products to the atomic force microscopy (AFM) market. In the
past year and a half, BioForce has released the Nano eNabler molecular
printer. BioForce technology is being used in sensor functionalization, ECM
(extracellular matrix) patterning and cell adhesion; printing proteins to
guide neural cell growth; printing signaling proteins to study stem cell
differentiation, multilayer soft lithography, and microfluidics devices;
and printing patterns of ECM proteins on different substrates to study the
effect on human embryonic stem cells (hESCs) growth and differentiation to
name a few.
About BioForce Nanosciences, Inc.
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce
Nanosciences Holdings, Inc. (BFNH.OB). BioForce Nanosciences is a unique
company entering into commercialization with over a decade of research and
accomplishment in the field of bionanotechnology. BioForce has demonstrated
the ability to take a product from concept to commercial sale. For more
information, visit http://www.bioforcenano.com .
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
For more information, please click here
BioForce Nanosciences, Inc.
1615 Golden Aspen Drive, Suite 101
Ames, IA 50010 USA
Phone: 515.233.8333 ext. 101
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017
Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017
Engineers shrink microscope to dime-sized device February 17th, 2017
Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017